Results 241 to 250 of about 541,793 (303)

Unmasking Malaria: Microscopy and nPCR Reveal the Hidden Misdiagnosis of Plasmodium Infections Among Febrile Pediatric in Northwest Ethiopia

Interdisciplinary Perspectives on Infectious Diseases
Sisay Getie, Gebeyaw Getnet Mekonnen, Ligabaw Worku, Meseret Birhanie, Aline Lamien Meda, Aberham Abere, Harald Noedl   +6 more
doaj   +1 more source

Is single-shot antibiotic prophylaxis really enough for standard OMF-surgeries? [PDF]

Clin Oral Investig
Schorn L, Singh DD, Mrochen F, Kempe M, Schrader F, Rana M, Sproll C, Lommen J, Joost I.   +8 more
europepmc   +1 more source

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 Genotype and Use of 5‐HT3 Receptor Antagonists: 2026 Update

Clinical Pharmacology &Therapeutics, EarlyView.
5‐hydroxytryptamine type 3 (5‐HT3) receptor antagonists are used to treat nausea and vomiting and in the prevention of chemotherapy‐induced, radiation‐induced, and postoperative nausea and vomiting. Most of the 5‐HT3 receptor antagonists (i.e., ondansetron, tropisetron, dolasetron, palonosetron, and ramosetron) are metabolized by CYP2D6, but the extent
Claire Moore, Melissa S. Bourque, Andreas Halman, José A. G. Agúndez, Cynthia A. Prows, Keiko Hikino, Matthias Schwab, Carolyn J. Oxencis, Dharmisha Chauhan, Meta H.M. Diekstra, Susie E. Long, Gillian C. Bell, Andrea Gaedigk, Michelle Whirl‐Carrillo, Teri E. Klein, Kelly E. Caudle, Rachel Conyers   +16 more
wiley   +1 more source

Evaluation of the clinical performance of a risk scoring model for venous thromboembolism prophylaxis in cesarean section for a largely Chinese population. [PDF]

Res Pract Thromb Haemost
Kong CW, To WWK.
europepmc   +1 more source

Transthyretin amyloid cardiomyopathy: Literature review and red‐flag symptom clusters for each cardiology specialty

ESC Heart Failure, Volume 12, Issue 2, Page 955-967, April 2025.
Abstract Wild‐type transthyretin amyloid cardiomyopathy (ATTRwt‐CM) is a progressive and infiltrative cardiac disorder that may cause fatal consequences if left untreated. The estimated survival time from diagnosis is approximately 3–6 years. Because of the non‐specificity of initial symptom manifestation and insufficient awareness among treating ...
Yasuhiro Izumiya, Toru Kubo, Jin Endo, Seiji Takashio, Masatoshi Minamisawa, Jun Hamada, Tomonori Ishii, Hajime Abe, Hiroaki Konishi, Kenichi Tsujita   +9 more
wiley   +1 more source

Adalimumab Therapy for Crohn's Disease and Axial Spondyloarthritis in Latent Tuberculosis: <i>A bibliometric-systematic literature review</i>. [PDF]

Sultan Qaboos Univ Med J
Shofa NM, Setiyari Mudjari N, Ekawati R, Arianti A, Zahra Mufida A, Widodo B, Sugihartono T.   +6 more
europepmc   +1 more source

Patient perspectives on post-operative direct oral anticoagulant for venous thromboembolism prevention in patients with gynecologic cancers undergoing laparotomy. [PDF]

Gynecol Oncol Rep
Black KA, Mateshaytis J, Sevick L, Rogers J, Bisch SP, Flasha P, Pin S.   +6 more
europepmc   +1 more source

Timing, risk, and reality: early venous thromboembolism chemoprophylaxis in patients with TBI requiring operative intervention. [PDF]

Trauma Surg Acute Care Open
Dhillon NK.
europepmc   +1 more source

Emicizumab prophylaxis in a preterm infant with severe hemophilia A: a case report on the feasibility of early use. [PDF]

Res Pract Thromb Haemost
Hassan E, Percy C, Ahmed A, Lowe G, Lester W, Morgan NV, Motwani J.   +6 more
europepmc   +1 more source